Cart
sales@molnova.com
MSAB
CAS No. 173436-66-3
MSAB( —— )
Catalog No. M22633 CAS No. 173436-66-3
MSAB is a selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes.MSAB act against Wnt/β-catenin signaling and identified as a selective inhibitor of Wnt/β-catenin signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 71 | In Stock |
|
| 2MG | 40 | In Stock |
|
| 5MG | 64 | In Stock |
|
| 10MG | 116 | In Stock |
|
| 25MG | 235 | In Stock |
|
| 50MG | 346 | In Stock |
|
| 100MG | 524 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1097 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMSAB
-
NoteResearch use only, not for human use.
-
Brief DescriptionMSAB is a selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes.MSAB act against Wnt/β-catenin signaling and identified as a selective inhibitor of Wnt/β-catenin signaling.
-
DescriptionMSAB is a selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes.MSAB act against Wnt/β-catenin signaling and identified as a selective inhibitor of Wnt/β-catenin signaling. MSAB shows potent anti-tumor effects selectively on Wnt-dependent cancer cells in vitro and in mouse cancer models. MSAB binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. might represent an effective therapeutic strategy for cancers addicted to the Wnt/β-catenin signaling pathway.
-
In VitroMSAB (2-10 μM) selectively decreases cell viability of Wnt-dependent cells while showing little effect on Wnt-independent cells and normal human cells. MSAB (0.01-10 μM; 20 h) inhibits T-cell factor (TCF) luciferase reporter activity in HCT116 cells. MSAB (20 h) suppresses the Wnt3a-induced TOP-Luc activation and increases of active β-catenin levels in HEK293T cells. MSAB (0.5-10 μM; 20 h) decreases mRNA and protein levels of endogenous Wnt target genes in HCT116 cells. MSAB (5 μM; 16 h) induces degradation of β-catenin in a proteasome-dependent manner in HCT116 cells.
-
In VivoMSAB (10-20 mg/kg; i.p. daily for 2 weeks) inhibits tumor growth of Wnt-dependent cancer cells in mouse xenograft model. MSAB (10-20 mg/kg; i.p. twice daily for 2 weeks) inhibits tumor growth of MMTV-Wnt1 transgenic mice. Animal Model:Athymic nude mice (5-6 weeks) are injected HCT116, HT115, H23, or H460 cells Dosage:10, 20 mg/kg Administration:I.p. dailyfor 2 weeks Result:Reduced the size and weight of various types of Wnt-dependent HCT116, HT115, and H23 tumors.
-
Synonyms——
-
PathwayWnt/Notch/Hedgehog
-
TargetWnt/beta/catenin
-
RecptorWnt/β-catenin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number173436-66-3
-
Formula Weight305.35
-
Molecular FormulaC15H15NO4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (818.73 mM)
-
SMILESCOC(=O)c1cccc(NS(=O)(=O)c2ccc(C)cc2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hwang SY, et, al. Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling. Cell Rep. 2016 Jun 28;16(1):28-36.
molnova catalog
related products
-
IWP-3
IWP-3 is a potent inhibitor of Wnt production with an IC50 of 40 nM. It inhibits Porcupine (Porcn), blocking the palmitoylation of Wnt proteins, and moderately inhibits CK1γ3 and CK1ε, but does not inhibit CK1α .
-
Wnt/β-catenin agonis...
Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and is an effective Wnt agonist.
-
Wnt pathway activato...
Wnt pathway activator 1 is a potent Wnt activator with an IC50 of 28-29 nM. Wnt pathway activator 1 is a potent Wnt activator for the treatment of androgenetic alopecia (AGA) extracted from patent WO2012024404A1.
